Posts by Noëlle Aubert

Stimulation of the nervous system with neurotechnology EPFL scientists in a European collaboration propose a personalised protocol for optimising stimulation of optic nerve fibers, for the blind, which takes into account feedback from the viewer’s brain. The protocol has been tested on artificial neural networks known to simulate the physiology of the entire visual system,…

High-energy electron beams can be focused onto deep-seated cancerous tumours   The study, conducted at CERN’s CLEAR test facility, demonstrates how very high-energy electron beams can be focused onto deep-seated cancerous tumours. There are some cancer tumours that not even surgery, chemotherapy or traditional radiation therapy can cure. These resistant tumours contribute to making the…

New office with 60 employees   In response to the investment boom in the pharmaceutical industry, Pharmaplan is opening another office in Switzerland in the third quarter of 2021. With the new subsidiary at the biotech site in Visp, Pharmaplan as Swiss market leader, is meeting the growing global demand for pharmaceutical engineering services and…

This article was written by Labiotech.eu with the support of BioAlps, the Greater Zurich Area, and Switzerland Global Enterprise (S-GE).   Switzerland has long been known as a booming biotech hotspot in Europe that boasts many high-profile companies. Here are the top 5 biotech companies among the new generation of promising startups in Western Switzerland.…

CHF 1.4 mio for biomedical research in the Lake Geneva region   The Leenaards Foundation has awarded Science Prizes to two research groups based in the Lake Geneva region. The prizes, worth a combined CHF 1.4 million in research funding. One of the winning projects, led by Prof. Grégoire Courtine, will investigate how to restore…

  HEIG-VD is joining forces with the EPFL and the University of Geneva (UNIGE) to take up the challenge of automating the production of cancer treatments. Recent advances in cell and gene therapy (CGT) represent a revolution in personalised medicine. These ‘living drugs’ are based on the latest knowledge in cell engineering and immunology. Made…

The most important prize for young entrepreneurs in Switzerland   From dozens of applications, nine companies were nominated for the final of Switzerland’s most important young entrepreneur award. Embion Technologies is proud to be among this year’s best in the category ‘Hightech/Biotech’.   About the Swiss Economic Award The Swiss Economic Award is the most…

Ethical & legal questions   Digital twins – a savvy combination of artificial intelligence and personal data – have already begun to revolutionise the way healthcare is provided. But they raise a lot of ethical and legal questions, especially given the vast amounts of medical data that must be collected to train artificial intelligence algorithms.…

Meet the Swiss national MedTech team   The Swiss National Startup Team has 10 new members: 10 startups were selected for the first Venture Leaders program dedicated explicitly to the medtech sector. In the fall, the Venture Leaders Medtech will embark on their roadshow to Boston and Cambridge to dive into the US medtech startup…

Sum used to develop targeted antibodies for cancer patients   Abologix develops a new therapeutic option to treat lymphoma patients who have become resistant to conventional treatments. The Geneva-based biotech startup is a spin-out from the laboratories at the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG). Abologix will use the CHF 150,000…